Remarkably, enhanced HBP was observed in several cancers, and its inhibition by either preventing consumption of glutamine [by glutamine analog, 6-diazo-5-oxo-L-norleucine (DON)] or targeting GFAT1/2 results in deterioration of tumor (Li et al., 2017; Asthana et al., 2018; Zhang et al., 2018). Here, GFPT1 is linked to cancer.